Selective inhibition of cholera toxin- and catecholamine-stimulated lipolysis by blocking agents.
Vibrio cholerae enterotoxin stimulates lipolysis in rat epididymal fat cell suspensions. Like hormones this toxin increases adenylate cyclase activity, raising levels of cyclic adenosine 3',5'-monophosphate (cAMP), which activates a cellular lipase. Using specific blocking agents, we studied the responses to the adrenergic lipolytic hormones epinephrine, norepinephrine, and isoproterenol, and to cholera toxin. All stimulators were used at 100 x threshold dose. Propranolol (34 muM), a beta blocking agent, inhibited epinephrine stimulation (P less than 0.001) but not that of toxin (P greater than 0.2). Choleragenoid (25 mug/ml), a natural toxoid of cholera toxin, blocked stimulation by toxin (P less than 0.001) but not that of the adrenergic agents (P greater than 0.2). A beta blocker, practolol (3 mM), inhibited stimulation by the catecholamines tested (P less than 0.005) but not that of toxin (P greater than 0.05). Higher concentrations of propranolol (340 muM) and the alpha blocking agents phenoxybenzamine (3 mM) and phentolamine (1.6 mM) inhibited all agonists (P less than 0.001). The response to theophylline was inhibited by all blockers (P less than 0.05) except propranolol at the lower concentration (34 muM). A combined beta and alpha blockade using propranolol and epinephrine together did not inhibit toxin-mediated lipolysis. It appears that stimulation by cholera toxin is independent of beta adrenergic receptors. A major inhibition of theophylline-mediated lipolysis by alpha blocking drugs indicated a nonspecific effect of these agents at the concentrations used. The uninhibited response to toxin in the presence of propranolol and epinephrine suggests a lack of relationship of the toxin receptor to either alpha or beta receptors.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002395:Catecholamines / Q000494:pharmacology*; D003864:Depression, Chemical; D004768:Enterotoxins / Q000494:pharmacology*; D004837:Epinephrine / Q000037:antagonists & inhibitors; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D050356:Lipid Metabolism; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010646:Phentolamine / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D011941:Receptors, Adrenergic; D013806:Theophylline / Q000037:antagonists & inhibitors; D014734:Vibrio cholerae
D002395:Catecholamines; D004768:Enterotoxins; D011941:Receptors, Adrenergic; D011433:Propranolol; D013806:Theophylline; D000262:Adenylyl Cyclases; D007545:Isoproterenol; D011217:Practolol; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine